Sanofi (SNY) Restructuring Costs (2009 - 2026)

Sanofi has disclosed Restructuring Costs across 18 years of filings, most recently posting -$516.1 million for Q2 2026.

• In Q2 2026, Restructuring Costs fell 40.28% year-over-year to -$516.1 million; the TTM figure through Jun 2026 stood at -$2.9 billion (down 25.69% YoY), while the FY2025 annual figure was -$1.3 billion, up 12.33% from the prior year.
• Restructuring Costs came in at -$516.1 million for Q2 2026 at Sanofi, down from -$371.1 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of -$158.1 million in Q3 2024 to a low of -$1.5 billion in Q4 2024.
• Average Restructuring Costs over 5 years is -$616.4 million, with a median of -$442.7 million recorded in 2022.
• The largest YoY upside for Restructuring Costs was 54.74% in 2025 against a maximum downside of 345.02% in 2025.
• Over 5 years, Restructuring Costs stood at -$1.2 billion in 2022, then increased by 6.84% to -$1.1 billion in 2023, then slumped by 34.61% to -$1.5 billion in 2024, then grew by 11.2% to -$1.3 billion in 2025, then surged by 61.04% to -$516.1 million in 2026.
• Per Business Quant data, the three most recent Restructuring Costs figures were -$516.1 million in Q2 2026, -$371.1 million in Q1 2026, and -$1.3 billion in Q4 2025.